Association between SCN1A gene polymorphisms and drug resistant epilepsy in pediatric patients.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Seizure

• Publication date

  2018-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.seizure.2018.01.002PMID 29353705
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms and Regulation of Alternative Pre-mRNA Splicing.

  2015cited by this paper
• Genetic Biomarkers in Epilepsy

  2014cited by this paper
• A validation of the new definition of drug‐resistant epilepsy by the International League Against Epilepsy

  2014cited by this paper
• The puzzle(s) of pharmacoresistant epilepsy

  2013cited by this paper
• SCN1A variations and response to multiple antiepileptic drugs

  2013cited by this paper
• Predicting pharmacoresistance in pediatric epilepsy

  2013cited by this paper
• Cleavage and polyadenylation specificity factor 1 (CPSF1) regulates alternative splicing of interleukin 7 receptor (IL7R) exon 6.

  2013cited by this paper
• Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population

  2011cited by this paper
• A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy

  2011cited by this paper
• Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy.

  2010cited by this paper
• Critical association of ncRNA with introns

  2010cited by this paper
• Epilepsy pharmacogenetics.

  2009cited by this paper
• Alternative splicing of G protein-coupled receptors: physiology and pathophysiology

  2009cited by this paper
• The clinical impact of pharmacogenetics on the treatment of epilepsy

  2009cited by this paper
• Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies

  2009cited by this paper
• Association between SCN1A polymorphism and carbamazepine-resistant epilepsy.

  2008cited by this paper
• Intrinsic Severity as a Determinant of Antiepileptic Drug Refractoriness

  2008cited by this paper
• Cryptogenic epileptic syndromes related to SCN1A: twelve novel mutations identified.

  2008cited by this paper
• Update on pharmacogenetics in epilepsy: a brief review.

  2006cited by this paper
• The potential of pharmacogenetics in the treatment of epilepsy.

  2006cited by this paper
• A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose

  2006cited by this paper
• Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.

  2005cited by this paper
• Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy.

  1989cited by this paper

• The association of SCN1A polymorphisms with epilepsy and drug resistance: a systematic review and meta-analysis

  2025cites this paper
• Sodium channel mutation SCN1A T875M, D188V and associated dysfunction with drug resistant epilepsy

  2025cites this paper
• Sodium channel modulation as a therapeutic strategy for chemotherapy-induced peripheral neurotoxicity

  2025cites this paper
• Molecular Insights of Drug Resistance in Epilepsy: Multi-omics Unveil

  2024cites this paper
• Association between Genetic Polymorphism of SCN1A, GABRA1 and ABCB1 and Drug Responsiveness in Vietnamese Epileptic Children

  2024cites this paper
• Pre-treatment risk predictors of valproic acid-induced dyslipidemia in pediatric patients with epilepsy

  2024cites this paper
• Drug-resistant epilepsy and its selected complications in children

  2024cites this paper
• SCN1A Polymorphisms and Haplotypes Are Associated With Valproic Acid Treatment Outcomes in Chinese Children With Epilepsy.

  2023cites this paper
• Association between SCN1A polymorphism and risk of epilepsy in children: A systematic review and meta-analysis.

  2023cites this paper
• Genetic influences on epilepsy outcomes: A whole‐exome sequencing and health care records data linkage study

  2023cites this paper
• The effect of cannabidiol on seizure features and quality of life in drug-resistant frontal lobe epilepsy patients: a triple-blind controlled trial

  2023cites this paper
• Genotype–Phenotype Analysis of Children with Epilepsy Referred for Whole-Exome Sequencing at a Tertiary Care University Hospital

  2023cites this paper
• Study of genetic variants and their clinical significance in Mexican pediatric patients with epilepsy.

  2023cites this paper
• The Promising Epigenetic Regulators for Refractory Epilepsy: An Adventurous Road Ahead

  2022cites this paper
• Genetic Analysis of Sodium Channel Genes in Pediatric Epilepsy Patients of Pakistan

  2022cites this paper
• ABCG2, SCN1A and CYP3A5 genes polymorphism and drug-resistant epilepsy in children: A case-control study.

  2022cites this paper
• The clinical and genetic features of SCN 1 A , SCN 2 A gene related phenotypes in patients with epilepsy and intellectual / developmental disability

  2022cites this paper
• Association of sodium voltage-gated channel genes polymorphisms with epilepsy risk and prognosis in the Saudi population

  2022cites this paper
• Potential clinical and biochemical markers for the prediction of drug-resistant epilepsy: A literature review.

  2022cites this paper
• Pharmacogenetics-based population pharmacokinetic analysis and dose optimization of valproic acid in Chinese southern children with epilepsy: Effect of ABCB1 gene polymorphism

  2022cites this paper
• NDT_A_256699 2229..2242

  2021cites this paper
• Clinical Management of Drug Resistant Epilepsy: A Review on Current Strategies

  2021cites this paper
• Association between autophagy-related protein 5 gene polymorphisms and epilepsy in Chinese patients.

  2021cites this paper
• Possible interplay between the theories of pharmacoresistant epilepsy

  2020cites this paper
• Genetic variations associated with pharmacoresistant epilepsy

  2020cites this paper
• Drug-resistant epilepsy: From multiple hypotheses to an integral explanation using preclinical resources.

  2019cites this paper
• Efficacy of antiepileptic drugs in the era of pharmacogenomics: A focus on childhood.

  2019cites this paper
• Mapping the knowledge structure and trends of epilepsy genetics over the past decade

  2019cites this paper
• A Systems Biology Approach for Personalized Medicine in Refractory Epilepsy

  2019cites this paper
• XI International Conference on Immunonutrition 2018: ISIN

  2018cites this paper
• The possible effect of sCn1a and sCn2a genetic variants on carbamazepine response among Khyber Pakhtunkhwa epileptic patients, Pakistan

  2018cites this paper
• SCN1A rs3812718 polymorphism is associated with epilepsy: An updated meta-analysis.

  2018cites this paper
• The possible effect of SCN1A and SCN2A genetic variants on carbamazepine response among Khyber Pakhtunkhwa epileptic patients, Pakistan

  2018cites this paper
• World Journal of Experimental Medicine

  year unknowncites this paper